Precoce Medical Care by the Mobil Support for Patients With Glioblastoma
NCT04516733 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 35
Last updated 2022-03-14
Summary
Most patients with glioblastoma have impaired cognitive function, autonomy, and quality of life.
This clinical situation, combined with a limited life expectancy, makes the preservation of quality of life a major objective, in a supportive environment that respects family integration. This is especially true since there is an established relationship between health-related quality of life, as measured by questionnaires.
In this context, and despite the lack of impact on overall survival, improving quality of life becomes a priority objective in recent Phase III trials.
The feasibility of introducing early accompaniment in GBM should be assessed in the diagnostic and therapeutic announcement environment. In order to measure the expected impact as favorable in the patient and his family, a broad survey of the classic domains of quality of life and more specifically dedicated to neurological symptomatology.
Conditions
Interventions
- OTHER
-
supportive care
visit with supportiv unit and neuropsychologue every 3 months
Sponsors & Collaborators
-
Institut du Cancer de Montpellier - Val d'Aurelle
lead OTHER
Principal Investigators
-
Michel FABBRO, MD · Institut du Cancer de Montpellier - Val d'Aurelle
Study Design
- Allocation
- NA
- Purpose
- SUPPORTIVE_CARE
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-05-10
- Primary Completion
- 2020-09-15
- Completion
- 2022-02-15
Countries
- France
Study Locations
More Related Trials
-
A Randomized Trial of Delayed Radiotherapy in Patients Low-grade Oligodendrogliomas Requiring a Treatment Other Than Surgery
NCT04702581 ·Status: RECRUITING ·Phase: PHASE3
-
Procarbazine and Lomustine in Recurrent Glioblastoma
NCT01737346 ·Status: UNKNOWN ·Phase: PHASE2
-
Molecular Genetic, Host-derived and Clinical Determinants of Long-term Survival in Glioblastoma
NCT03770468 ·Status: COMPLETED
-
Temozolomide and Procarbazine With Cilengitide for Patients With Glioblastoma Multiforme Without Methylation of the MGMT Promoter Gene
NCT01124240 ·Status: UNKNOWN ·Phase: PHASE2
-
Simultaneous Integrated Boost FDOPA Positron Emission Tomography (PET) Guided in Patients With Partially- or Non-operated Glioblastoma
NCT05653622 ·Status: RECRUITING ·Phase: PHASE2
-
Early Integration of Palliative Care Using the BEACON PROQOL in Patients With High Grade Glioma and Their Caregivers
NCT04630379 ·Status: COMPLETED ·Phase: NA
-
IA Carboplatin + Radiotherapy in Relapsing GBM
NCT03672721 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Oxidative Phosphorylation Targeting In Malignant Glioma Using Metformin Plus Radiotherapy Temozolomide
NCT04945148 ·Status: RECRUITING ·Phase: PHASE2
-
Imaging Study of the Distribution of IL13-PE38QQR Infused Before and After Surgery in Adult Patients With Recurrent Malignant Glioma
NCT00064779 ·Status: COMPLETED ·Phase: PHASE1
-
Immunological and Functional Characterization of Cellular Population CD45+ Infiltrating Human Glioblastoma
NCT03687099 ·Status: COMPLETED
-
Retrospective Evaluation of Melanocortin Receptor 4 Polymorphisms in Patients With GBM Treated With Radiochemotherapy
NCT02458508 ·Status: COMPLETED
-
Histologic Effect/Safety of Pre/Post-Operative IL13-PE38QQR in Recurrent Resectable Supratentorial Malignant Glioma Patients
NCT00024557 ·Status: COMPLETED ·Phase: PHASE1
-
Artificial Intelligence-Guided Radiotherapy Planning for Glioblastoma
NCT06657027 ·Status: NOT_YET_RECRUITING
-
Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Unmethylated Gene Promoter Status
NCT00813943 ·Status: COMPLETED ·Phase: PHASE2
-
Metformin, Neo-adjuvant Temozolomide and Hypo- Accelerated Radiotherapy Followed by Adjuvant TMZ in Patients With GBM
NCT02780024 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Disease Progression and Treatment-induced Alterations in Glioblastoma
NCT02152748 ·Status: UNKNOWN
-
Glioblastoma Treatment With Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated Patients
NCT04121455 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.
NCT05109728 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma
NCT01878617 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma
NCT07301268 ·Status: RECRUITING ·Phase: PHASE2
-
Randomized Phase 2 With CpG-ODN in Malignant Glioblastoma
NCT00190424 ·Status: COMPLETED ·Phase: PHASE2
-
Low Dose Radiation Therapy for Glioblastoma Multiforme
NCT01466686 ·Status: COMPLETED ·Phase: PHASE2
-
Hypofractionated Stereotactic Radiotherapy in Recurrent Glioblastoma Multiforme
NCT01464177 ·Status: COMPLETED ·Phase: PHASE2
-
Convection-Enhanced Delivery of 124I-Omburtamab for Patients With Non-Progressive Diffuse Pontine Gliomas Previously Treated With External Beam Radiation Therapy
NCT01502917 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Evaluate Safety and Activity of Crizotinib With Temozolomide and Radiotherapy in Newly Diagnosed Glioblastoma
NCT02270034 ·Status: COMPLETED ·Phase: PHASE1